A method for stimulating bone formation by administering integrin binding compounds which cause the release of osteocalcin from osteoblasts is disclosed.
A compound of the formula (I) is disclosed which is a vitronectin receptor antagonist and is useful in the treatment of osteoporosis:
1
or a pharmaceutically acceptable salt thereof.
[EN] VITRONECTIN RECEPTOR ANTAGONIST<br/>[FR] ANTAGONISTE DU RECEPTEUR DE VITRONECTINE
申请人:SMITHKLINE BEECHAM CORPORATION
公开号:WO1999015170A1
公开(公告)日:1999-04-01
(EN) A compound of formula (I) is disclosed which is a vitronectin receptor antagonist and is useful in the treatment of osteoporosis or a pharmaceutically acceptable salt thereof.(FR) L'invention concerne un composé représenté par la formule (I) qui est un antagoniste du récepteur de vitronectine, utile pour le traitement de l'ostéoporose: (I), ou un sel pharmaceutiquement acceptable de ce composé.